AbbVie’s Skyrizi is approved by the FDA for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease.

New products Skyrizi and Rinvoq help AbbVie cope with accelerating erosion of Humira sales from biosimilar competition in 2023.